Delving into the Latest Updates on PLIVA Croatia Ltd. with Synapse

A multicenter, randomized, open label, two treatment, two period, single-dose, crossover, bioequivalence study of Azacitidine Tablets 300 mg manufactured by Teva, Czech Industries s.r.o. with ONUREG (Azacitidine) Tablets 300 mg manufactured by Celgene Distribution B.V., Netherlands under fasting condition in patients with a confirmed diagnosis of Acute Myeloid Leukemia in remission phase. - NIL

开始日期2024-04-15

申办/合作机构

PLIVA Croatia Ltd.

CTR20233083 / Recruiting临床1期

一项评估 TV-44749（奥氮平缓释注射用混悬液）在中国精神分裂症患者中的安全性、耐受性和药代动力学的 I 期、单剂量、平行队列研究

评估皮下注射用奥氮平缓释混悬液 (TV-44749) 单次给药用于中国精神分裂症患者的安全性, 耐受性及药代动力学。

开始日期2024-03-28

申办/合作机构

Teva Branded Pharmaceutical Products R&D, Inc.

[+2]

CTR20232834 / Active, not recruiting临床3期

一项评价 TV-44749 治疗精神分裂症成人患者的有效性和安全性的随机、双盲、安慰剂对照研究，包括一个开放标签、长期安全性阶段

:精神分裂症是一种使人衰弱的重度精神病性障碍，其特征包括阳性和阴性症状，全球终生发病风险约为 1%。对于大多数患者来说，这一疾病伴有需要长期使用抗精神病药物治疗的慢性病程。不依从和不遵守长期口服药物治疗方案是精神分裂症和相关疾病治疗中最重要的治疗问题，导致这些患者中的许多频繁复发或加重，且无法从抗精神病药物治疗中完全获益。缓释注射用抗精神病药物可能会提高精神分裂症患者的依从性。目前，奥氮平的口服、长效肌肉注射 (im) 和速效 im 制剂被批准用于治疗患有精神分裂症的成人。一种用于皮下注射 (sc) 的奥氮平缓释混悬液新制剂 (TV-44749) 旨在用于治疗精神分裂症。

开始日期2023-12-22

申办/合作机构

Teva Branded Pharmaceutical Products R&D, Inc.

[+2]

100 项与 PLIVA Croatia Ltd. 相关的临床结果

登录后查看更多信息

0 项与 PLIVA Croatia Ltd. 相关的专利（医药）

登录后查看更多信息

72

项与 PLIVA Croatia Ltd. 相关的文献（医药）

2024-04-01·International Journal of Pharmaceutics

Synergism of polysaccharide polymers in antihistamine eye drops: Influence on physicochemical properties and in vivo efficacy

Article

作者: Krajišnik, Danina ; Stepanović-Petrović, Radica ; Vučen, Sonja ; Pecikoza, Uroš ; Jurišić Dukovski, Bisera ; Bajac, Jelena ; Lovrić, Jasmina ; Račić, Anđelka ; Tomić, Maja ; Micov, Ana ; Dobričić, Vladimir

The incorporation of polymers into drug delivery vehicles has been shown to be a useful approach to prolong the residence time of drugs in the precorneal tear film and to improve penetration into biological membranes. The main objective of this research was to formulate novel viscous eye drops with ketotifen as the active ingredient, containing the polysaccharides: chitosan (MCH), hydroxypropyl guar gum (HPG) and hyaluronic acid (SH) alone and in combination as functional polymers. DSC and FT-IR techniques showed the compatibility between ketotifen and polymers. Physicochemical and rheological analysis at ambient and simulated physiological conditions, as well as the evaluation of mucoadhesive properties showed that vehicles containing combinations of polymers have suitable physicochemical and functional properties with demonstrated synergism between combined polymers (MCH and HPG i.e. SH and HPG). The drug permeability was successfully estimated in vitro using HCE-T cell-based models. MTT cytotoxicity assay demonstrates that the tested formulations were non-toxic and well tolerated. In vivo preclinical study on mice revealed that both vehicles containing mixed polymers enhanced and prolonged the antipruritic/analgesic-like effect of ophthalmic ketotifen. Based on these results, both combinations of polysaccharide polymers, especially SH-HPG, could be considered as potential new carriers for ketotifen for ophthalmic use.

2023-10-04·Chemical and Biochemical Engineering Quarterly

Amoxicillin Biodegradation with Bacillus subtilis and Pseudomonas aeruginosa: Characterization of Relevant Degradation Products

作者: Vuković Domanovac, M. ; Kovačić, Simona ; Lovrinčević, Vilma ; Vuk, Dragana

2023-04-28·Pharmaceutics

A Novel Approach for the Treatment of Aerobic Vaginitis: Azithromycin Liposomes-in-Chitosan Hydrogel.

Article

作者: Jøraholmen, May Wenche ; Uzelac, Lidija ; Kralj, Marijeta ; Vanić, Željka ; Rukavina, Zora ; Keser, Sabina ; Škalko-Basnet, Nataša ; Šegvić Klarić, Maja ; Amidžić Klarić, Daniela ; Čačić, Ana ; Radiković, Maja

Biocompatible mucoadhesive formulations that enable a sustained drug delivery at the site of action, while exhibiting inherent antimicrobial activity, are of great importance for improved local therapy of vaginal infections. The aim of this research was to prepare and evaluate the potential of the several types of azithromycin (AZM)-liposomes (180-250 nm) incorporated into chitosan hydrogel (AZM-liposomal hydrogels) for the treatment of aerobic vaginitis. AZM-liposomal hydrogels were characterized for in vitro release, and rheological, texture, and mucoadhesive properties under conditions simulating the vaginal site of application. The role of chitosan as a hydrogel-forming polymer with intrinsic antimicrobial properties was explored against several bacterial strains typical for aerobic vaginitis as well as its potential effect on the anti-staphylococcal activity of AZM-liposomes. Chitosan hydrogel prolonged the release of the liposomal drug and exhibited inherent antimicrobial activity. Additionally, it boosted the antibacterial effect of all tested AZM-liposomes. All AZM-liposomal hydrogels were biocompatible with the HeLa cells and demonstrated mechanical properties suitable for vaginal application, thus confirming their potential for enhanced local therapy of aerobic vaginitis.

100 项与 PLIVA Croatia Ltd. 相关的药物交易

登录后查看更多信息

100 项与 PLIVA Croatia Ltd. 相关的转化医学

登录后查看更多信息